These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36898872)

  • 1. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
    Hannan R; McLaughlin MF; Pop LM; Pedrosa I; Kapur P; Garant A; Ahn C; Christie A; Zhu J; Wang T; Robles L; Durakoglugil D; Woldu S; Margulis V; Gahan J; Brugarolas J; Timmerman R; Cadeddu J
    Eur Urol; 2023 Sep; 84(3):275-286. PubMed ID: 36898872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
    Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
    Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
    Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney.
    Tan VS; Correa RJM; Warner A; Ali M; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; Suk Kwon Y; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Hannan R; Staehler M; Zaorsky NG; Louie AV; Siva S
    Eur Urol Oncol; 2024 Dec; 7(6):1527-1534. PubMed ID: 38987159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
    Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
    Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
    Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S
    Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
    Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
    BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
    Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
    Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
    Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiation therapy for primary renal cell carcinoma: A review on behalf of the CC-AFU.
    Bentahila R; Bensalah K; Benziane-Ouaritini N; Barthelemy P; Rioux-Leclerc N; Correas JM; Belhomme S; Bigot P; Sargos P
    Fr J Urol; 2024 Jul; 34(7-8):102660. PubMed ID: 38823486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
    Siva S; Bressel M; Wood ST; Shaw MG; Loi S; Sandhu SK; Tran B; A Azad A; Lewin JH; Cuff KE; Liu HY; Moon D; Goad J; Wong LM; LimJoon M; Mooi J; Chander S; Murphy DG; Lawrentschuk N; Pryor D
    Eur Urol; 2022 Apr; 81(4):364-372. PubMed ID: 34953600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
    Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
    Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.
    Correa RJM; Ahmad B; Warner A; Johnson C; MacKenzie MJ; Pautler SE; Bauman GS; Rodrigues GB; Louie AV
    Radiat Oncol; 2018 Mar; 13(1):47. PubMed ID: 29558966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial.
    Siva S; Pham D; Kron T; Bressel M; Lam J; Tan TH; Chesson B; Shaw M; Chander S; Gill S; Brook NR; Lawrentschuk N; Murphy DG; Foroudi F
    BJU Int; 2017 Nov; 120(5):623-630. PubMed ID: 28188682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
    Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
    Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer.
    Ali M; Kwon YS; Koo K; Bruynzeel A; Pryor D; Schep DG; Huo M; Stein M; Swaminath A; Hannan R; Siva S
    BJU Int; 2025 Jan; 135(1):110-116. PubMed ID: 39187428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study.
    Choi SH; Lee BM; Kim J; Kim DY; Seong J
    J Hepatol; 2024 Jul; 81(1):84-92. PubMed ID: 38467379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.